Page 7 - காரணிகள் அந்த இருக்கலாம் செயல்விளைவு உண்டுபண்ணு எதிர்கால News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from காரணிகள் அந்த இருக்கலாம் செயல்விளைவு உண்டுபண்ணு எதிர்கால. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In காரணிகள் அந்த இருக்கலாம் செயல்விளைவு உண்டுபண்ணு எதிர்கால Today - Breaking & Trending Today

Pfizer Provides Update on U.S. FDA Review of Abrocitinib and XELJANZ® Filings


Pfizer Provides Update on U.S. FDA Review of Abrocitinib and XELJANZ® Filings
Pfizer Inc. announced today that the U.S. Food and Drug Administration has notified the company that it will not meet the Prescription Drug User Fee Act goal dates for the New Drug Application for abrocitinib for the treatment of adults and adolescents with moderate to severe atopic dermatitis and the supplemental New Drug Application for XELJANZXELJANZ XR for the treatment of adults with active ankylosing …
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has notified the company that it will not meet the Prescription Drug User Fee Act (PDUFA) goal dates for the New Drug Application for abrocitinib for the treatment of adults and adolescents with moderate to severe atopic dermatitis and the supplemental New Drug Application for XELJANZ/XELJANZ XR (tofacitinib) for the treatment of adults with active ankylosing spondylitis. The FDA cited its ongoing rev ....

Michael Corbo , Bryan Dunn , Steve Danehy , Exchange Commission , Pfizer Inc , Drug Administration , Pfizer Global Product Development , Prescription Drug User Fee Act , New Drug Application , Chief Development Officer , Pfizer Global Product , Barr Virus Associated , Non Steroidal Anti Inflammatory Drugs , Enzyme Elevations , Important Safety Information , Prescribing Information , Medication Guide , Breakthroughs That Change Patient Lives , Pfizer News , Annual Report , Looking Information , Factors That May Affect Future , Accessed July , மைக்கேல் கார்போ , பிரையன் டன் , ஸ்டீவ் டநேய ,